NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Neuraxis, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$7.85+0.15 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $95.14M
- P/E (TTM)
- –
- Dividend yield
- –
Neuraxis statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Electromedical & Electrotherapeutic Apparatus companies for comparison
Valuation
| Measure | Neuraxis | Industry median |
|---|---|---|
| Market Cap | $98.58M | $230.55M |
| Enterprise Value | $90.30M | $202.97M |
| PS Ratio | 18.54 | 3.10 |
| PB Ratio | 14.64 | 3.04 |
| P/TBV Ratio | 15.22 | 4.43 |
Enterprise value
| Measure | Neuraxis | Industry median |
|---|---|---|
| EV / Sales | 16.99 | 2.91 |
Income (trailing twelve months)
| Measure | Neuraxis | Industry median |
|---|---|---|
| Revenue | $5.32M | $102.39M |
| Gross Profit | $4.55M | $60.36M |
| Operating Income | -$7.68M | -$4.31M |
| Net Income | -$7.68M | -$6.57M |
| EBITDA | -$7.61M | -$1.98M |
| EPS (Diluted) | -$0.79 | -$0.08 |
Margins
| Measure | Neuraxis | Industry median |
|---|---|---|
| Gross Margin | 85.6% | 55.2% |
| Operating Margin | -144.5% | -6.04% |
| Profit Margin | -144.4% | -10.5% |
| EBITDA Margin | -143.1% | -2.67% |
Returns
| Measure | Neuraxis | Industry median |
|---|---|---|
| Return on Equity (ROE) | -139.8% | -18.2% |
| Return on Assets (ROA) | -89.9% | -13.3% |
| Return on Capital Employed (ROCE) | -111.3% | -9.07% |
Growth
| Measure | Neuraxis | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 65.2% | 8.85% |
| Revenue Growth (3Y CAGR) | 9.96% | 7.08% |
Balance sheet
| Measure | Neuraxis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.32M | $36.66M |
| Total Debt | $42.73K | $97.65M |
| Net Cash (Debt) | $8.28M | $3.92M |
| Net Cash Per Share | $0.66 | $0.28 |
| Equity (Book Value) | $6.74M | $55.33M |
| Book Value Per Share | $0.54 | $2.87 |
| Tangible Book Value | $6.48M | $10.79M |
| Working Capital | $6.32M | $56.72M |
Financial position
| Measure | Neuraxis | Industry median |
|---|---|---|
| Current Ratio | 3.04 | 2.48 |
| Quick Ratio | 2.83 | 1.53 |
| Debt / Equity | 0.01 | 0.41 |
| Interest Coverage | -73.67 | -1.85 |
Cash flow (trailing twelve months)
| Measure | Neuraxis | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.62M | -$566.22K |
Efficiency
| Measure | Neuraxis | Industry median |
|---|---|---|
| Asset Turnover | 0.62 | 0.58 |
| Inventory Turnover | 3.76 | 2.21 |
| Revenue Per Employee | $221.51K | $322.92K |
| Profits Per Employee | -$319.94K | -$51.88K |
| Employee Count | 24 | 185 |
Dividends and yields
| Measure | Neuraxis | Industry median |
|---|---|---|
| Earnings Yield | -7.79% | -6.88% |
| Buyback Yield | -7.90% | 0.78% |
| Shareholder Yield | -7.90% | 0.80% |
Shares
| Measure | Neuraxis | Industry median |
|---|---|---|
| Shares Outstanding | 12,557,800 | 44,302,700 |
| Shares Change (YoY) | 43.2% | 3.36% |
| Shares Change (QoQ) | 8.89% | 0.27% |
| Float | 7,549,320 | 37,462,700 |
| Shares Held by Insiders | 39.9% | 10.5% |
| Shares Held by Institutions | 21.7% | 63.5% |
Scores
| Measure | Neuraxis | Industry median |
|---|---|---|
| Altman Z-Score | 7.13 | 1.95 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Neuraxis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.